Literature DB >> 6403358

Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells.

Y Ron, P De Baetselier, E Tzehoval, J Gordon, M Feldman, S Segal.   

Abstract

Mice injected from day of birth onwards with rabbit anti-mouse IgM (antim-mu) antibodies were found to be B cell-deficient and defective for the induction of antigen-reactive proliferating T cells (TPRLF). This defective induction was not due to the absence of circulating antigen-specific antibodies since the daily injections of such antibodies during exposure to antigen did not restore the ability of anti-IgM treated animals to generate TPRLF. Analyzing the cellular events implicated in the induction of virgin antigen-reactive T cells, anti-mu-treated mice manifested impairment of the three interacting cell types involved in the induction of TPRLF. Thus, peritoneal and splenic antigen-presenting cells from such animals were impaired in their capacity to signal a primary antigen-specific T cell reaction. Their splenic lymphocytes could not function as initiator cells in transferring immunogenic signals to recruit TPRLF in normal recipients. Potent antigen-specific splenic initiator cells failed to induce the recruitment of specific TPRLF in anti-mu-treated mice. The defective induction of TPRLF in anti-mu-treated mice may be due to a functional impairment of cells expressing membrane-bound IgM molecules which seemingly play a central role in the transfer of immunogenic signals for the recruitment of antigen-specific circulating T cells. We suggest that splenic B cells function as initiators in the transfer of antigen-induced signals from peritoneal antigen-presenting cells to T cells. These seems to be the primary targets of anti-mu treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403358     DOI: 10.1002/eji.1830130214

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Treating human autoimmune disease by depleting B cells.

Authors:  R J Looney
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

2.  Establishment of functional T cells in SCID mice does not lead to termination of pregnancy.

Authors:  C M Hetherington; D W Dresser
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  The role of antibodies in the regulation of delayed-type hypersensitivity.

Authors:  Y Morikawa; K Kuribayashi; F Yoshikawa; K Fujita; A Mizushima; K Kakudo
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

4.  Polarized helper-T-cell responses against Leishmania major in the absence of B cells.

Authors:  D R Brown; S L Reiner
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

5.  A two-step, two-signal model for the primary activation of precursor helper T cells.

Authors:  P A Bretscher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

6.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

7.  Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells.

Authors:  W Y Ho; M P Cooke; C C Goodnow; M M Davis
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

8.  A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation.

Authors:  D J Cassell; R H Schwartz
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

9.  Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant.

Authors:  Yi Yang; Catherine R Back; Melissa A Gräwert; Ayla A Wahid; Harriet Denton; Rebecca Kildani; Joshua Paulin; Kristin Wörner; Wolgang Kaiser; Dmitri I Svergun; Asel Sartbaeva; Andrew G Watts; Kevin J Marchbank; Jean M H van den Elsen
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.